Portal de Periódicos da CAPES

Supervised injecting facilities: how much evidence is enough?

2007; Wiley; Volume: 26; Issue: 4 Linguagem: Inglês

10.1080/09595230701373818

1465-3362

Lisa Maher, Allison M. Salmon,

Opioid Use Disorder Treatment

Drug and Alcohol ReviewVolume 26, Issue 4 p. 351-353 Free Access Supervised injecting facilities: how much evidence is enough? Lisa Maher, Corresponding Author Lisa Maher National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine University of New South Wales Sydney Australia Lisa Maher PhD, Associate Professor and Program Head, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia, Allison Salmon PhD candidate, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales.National Centre in HIV Epidemiology and Clinical Research, St Vincent's Medical Centre, Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia. E-mail: [email protected]Search for more papers by this authorAllison Salmon, Allison Salmon National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine University of New South Wales Sydney Australia Lisa Maher PhD, Associate Professor and Program Head, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia, Allison Salmon PhD candidate, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales.Search for more papers by this author Lisa Maher, Corresponding Author Lisa Maher National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine University of New South Wales Sydney Australia Lisa Maher PhD, Associate Professor and Program Head, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia, Allison Salmon PhD candidate, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales.National Centre in HIV Epidemiology and Clinical Research, St Vincent's Medical Centre, Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia. E-mail: [email protected]Search for more papers by this authorAllison Salmon, Allison Salmon National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine University of New South Wales Sydney Australia Lisa Maher PhD, Associate Professor and Program Head, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia, Allison Salmon PhD candidate, National Centre in HIV Epidemiology and Clinical Research and School of Public Health and Community Medicine, University of New South Wales.Search for more papers by this author First published: 29 May 2009 https://doi.org/10.1080/09595230701373818Citations: 17 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References [1] Strathdee SA, Pollini R. A 21st century Lazarus: the role of safer injecting sites in harm reduction and recovery. Addiction, in press. [2] Kerr T., Tyndall M., Li K., Montaner J., Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005; 366: 316– 8. [3] Stoltz J., Wood E., Small W., et al. Changes in injecting practices associated with use of a medically supervised safer injection facility. J Public Health (Oxf) 2007; 29: 35– 9. [4] Hedrich D. European report on drug consumption rooms. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2004. [5] Wood E., Kerr T., Small W., et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Can Med Assoc J 2004; 171: 731– 4. [6] Thein H-H, Kimber J., Maher L., MacDonald M., Kaldor JM. Public opinion towards supervised injecting centres and the Sydney Medically Supervised Injecting Centre. Int J Drug Policy 2005; 16: 275– 80. [7] Wood E., Tyndall MW, Zhang R., et al. Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med 2006; 354: 2512– 4. [8] Wood E., Tyndall M., Lai C., Montaner J., Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy 2006; 1: 1– 4. [9] Kerr T., Stoltz J., Tyndall M., et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ 2006; 332: 220– 2. [10] ABC News Online. High hopes for injection centres. Available at: http:www.abc.net.aunewsindepthfeatureitemsinjecting.htm (accessed 12 March 2007). [11] Health Canada News Release. No new injection sites for addicts until questions answered, says Minister Clement. Available at: http:www.hc-sc.gc.caahc-ascmedianr-cp20062006_85_e.html (accessed 12 March 2007). [12] NCHECR. Sydney Medically Supervised Injecting Centre Interim Report 1: operations and service delivery (November 2002-December 2004). Sydney: University of NSW, 2005. [13] Salmon A., Thein H-H, Kimber J., Kaldor J., Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre Int J Drug Policy 2007; 18: 46– 53. [14] Deren S., Kang SY, Colon HM, Andia JF, Robles RR. HIV incidence among high-risk Puerto Rican drug users: a comparison of East Harlem, New York, and Bayamon, Puerto Rico. J Acquir Immune Defic Syndr 2004; 36: 1067– 74. [15] Maher L., Chant K., Jalaludin B., Sargent P. Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol 2004; 19: 1114– 20. [16] Maher L., Jalaludin B., Chant K., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101: 1499– 508. Citing Literature Volume26, Issue4July 2007Pages 351-353 ReferencesRelatedInformation